This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Researchers are experimenting with biologics—larger biological molecules that can do things smallmolecules can't, like targeting larger, more complex structures on cell surfaces or even inside cells. Understanding why these targets are resistant to current therapeutic strategies is crucial.
Researchers from the Laboratory of Bacteriology at The Rockefeller University have now found that bacteria sense phages by a defensive response named CBASS (cyclic oligonucleotide-based antiphage signalling system) which detects viral RNA. In bacteria , cGAS-like cyclases are central parts of the CBASS immuneresponse.
As soon as I learned about DNA and RNA, I wanted to be a molecular biologist. Last stops at RNA My last roles in biotech were where my original passion began: DNA and RNA. My last stop at Arrakis Therapeutics is with a company targeting RNA with smallmolecules. Arrakis is the capstone of my career.
In simple terms, our immune system is divided into innate and adaptive responses – the innate being the first line of defence, and the adaptive responds to specific challenges by modifying the body’s immuneresponse in a tailored fashion.
DNA and RNAmolecules are also built from exclusively right-handed nucleic acids. Glucose is a chiral molecule because its structure allows for two distinct configurations, or enantiomers, which cannot be superimposed on each other. The mirrored enzyme seamlessly transcribed 2,900 bases of mirrored DNA into mirrored RNA.
Immunization of non-human primates (rhesus macaques) with BNT162b2, a nucleoside-modified messenger RNA (modRNA) candidate that expresses the SARS-CoV-2 spike glycoprotein, resulted in strong anti-viral effects against an infectious SARS-CoV-2 challenge. producing CD8+ T cell responses, which is thought to promote an anti-viral effect.
When doctors sequenced the DNA and RNA found in Alice’s blood and synovial fluid—the liquid that surrounds and lubricates joints—they found abnormally low levels of genes encoding iron-storing proteins and high levels of epidermal growth factor receptor RNA.
In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immuneresponses similar to a traditional injection. Printed vaccines caused mice to have a faster immuneresponse. Read An easier (and cheaper) way to do single-cell RNA sequencing? Synthetic Biology.
In one experiment, the microneedle patches were used to deliver a SARS-CoV-2 vaccine into mice, producing immuneresponses similar to a traditional injection. Printed vaccines caused mice to have a faster immuneresponse. Read An easier (and cheaper) way to do single-cell RNA sequencing? Synthetic Biology.
The company and MiNA Therapeutics Limited announced a global research collaboration to develop novel drug candidates using MiNA’s proprietary small activating RNA (saRNA) technology platform. Business Development/Other Developments. The company announced the acquisition of Protomer Technologies Inc.,
BNT111 is the lead product candidate from BioNTech’s FixVac platform that targets a fixed combination of mRNA-encoded, tumor-associated antigens with the objective of triggering a strong and precise immuneresponse against cancer and is fully owned by BioNTech.
Galidesivir is a broad-spectrum antiviral, an adenosine nucleoside analog that blocks viral RNA polymerase. STP705 is a small interfering RNA (siRNA) therapy that leverages a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to knock down both TGF-beta1 and COX-2 gene expression.
Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and smallmolecules.
Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and smallmolecules. For more information, visit. www.merck.com. and connect with us on.
Link Experimental Tests of the Virtual Circular Genome Model for Nonenzymatic RNA Replication. Link Single-molecule visualization of stalled replication-fork rescue by the Escherichia coli Rep helicase. Link U1 snRNP increases RNA Pol II elongation rate to enable synthesis of long genes. Link Probing metabolism in an E.
Skin microbes can trigger strong immuneresponses. These microbes were engineered to express tumor antigens that could “elicit T cells that were licensed by the commensal immune program but specific for a tumor,” including both CD4+ and CD8+ T cells, according to the study. Nature Communications. Science Advances.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content